FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ENGLEMAN EDGAR	2. Date of Even Requiring State (Month/Day/Yea 09/16/2015	ment	3. Issuer Name and Ticker or Trace REGENXBIO Inc. [RG	Name and Ticker or Trading Symbol CNXBIO Inc. [RGNX]				
(Last) (First) (Middle) C/O REGENXBIO INC.			Relationship of Reporting Perso (Check all applicable) X Director	on(s) to Issue 10% Owne	(Mc	5. If Amendment, Date of Original Filed (Month/Day/Year)		
9712 MEDICAL CENTER DRIVE, SUITE 100	_		Officer (give title below)	Other (spe below)	App	dividual or Joint/Group Filing (Check licable Line) Form filed by One Reporting Person		
(Street) ROCKVILLE MD 20850						-	y More than One	
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			Amount of Securities eneficially Owned (Instr. 4) 3. Ownership Form: Direct (D or Indirect (I) (Instr. 5)		t (D) (Inst	4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exerc Expiration D (Month/Day/	ate	3. Title and Amount of Securit Underlying Derivative Security		4. Conversion or Exercise		6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Derivative or Indirect		
Series D Preferred Stock	(1)	(1)	Common Stock	826,341	(1)	I	See Footnote ⁽²⁾	
Series D Preferred Stock	(1)	(1)	Common Stock	114,108	(1)	I	See Footnote ⁽³⁾	

Explanation of Responses:

- 1. Each share of Preferred Series D Stock is convertible and will automatically convert on a 1:1 basis into the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock pursuant to an effective registration statement filed with the U.S. Securities and Exchange Commission. These shares have no expiration date.
- 2. The Reporting Person is a managing member of Vivo Capital VIII, LLC which is the sole general partner of Vivo Capital Fund VIII, L.P., the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise or such portion of the shares of common stock of the Issuer held by Vivo Capital Fund VIII, L.P. in which the Reporting Person has no pecuniary interest.
- 3. The Reporting Person is a managing member of Vivo Capital VIII, LLC which is the sole general partner of Vivo Capital Surplus Fund VIII, L.P., the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise or such portion of the shares of common stock of the Issuer held by Vivo Capital Surplus Fund VIII, L.P. in which the Reporting Person has no pecuniary interest.

Remarks:

<u>/s/ Edgar Engleman</u>

09/16/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.